Jeevan Scientific Technology Reports Strong FY26 Growth

Standalone net profit surged to ₹1.65 crore from ₹0.74 crore in FY26.
Standalone revenue increased by 23.7% to ₹53.93 crore in FY26.

Reader Takeaway: Significant profit and revenue growth is a positive, while continued scaling of operations is key for future gains.

What just happened

Jeevan Scientific Technology Limited announced its audited financial results for the fiscal year ended March 31, 2026. The company posted a substantial increase in both standalone and consolidated revenues and profits compared to the previous fiscal year.

Standalone revenue grew by approximately 23.7%, reaching ₹53.93 crore in FY26, up from ₹43.61 crore in FY25. Standalone net profit more than doubled, rising from ₹0.74 crore to ₹1.65 crore.

On a consolidated basis, revenue increased to ₹61.54 crore from ₹46.84 crore. The consolidated net profit saw a significant jump from ₹0.06 crore to ₹1.03 crore.

The company also approved the grant of 4,80,000 stock options to eligible employees under its ESOP scheme and allotted 1,61,250 equity shares upon exercise of options. M/s. KP & Associates was appointed as the internal auditor for FY 2026-27.

Why this matters

The strong double-digit growth in revenue and more-than-doubling of profits on a standalone basis indicate a healthy operational performance for Jeevan Scientific Technology. The positive consolidated results suggest a broader company-wide improvement. The ESOP grants signal a focus on employee retention and motivation, which can be crucial for sustained growth. An unmodified audit opinion from statutory auditors provides assurance on the reliability of the financial reporting.

The backstory

Jeevan Scientific Technology Limited operates in the clinical research services sector. Historically, the company has focused on expanding its service offerings and client base. Recent years have seen efforts to strengthen its financial position and operational efficiency to capitalize on the growing demand for clinical research outsourcing.

What changes now

Investors will be looking for continued execution of the company's business strategy, particularly in scaling its clinical research services segment. The financial performance in FY26 provides a strong base for future expectations. The company's ability to manage growth and maintain profitability will be key.

Risks to watch

While the results are positive, risks for companies in the clinical research sector include intense competition, regulatory changes, project delays, and the need for continuous investment in R&D and talent. The company's ability to effectively manage these factors will influence future performance.

Peer comparison

Jeevan Scientific Technology operates in a sector with several domestic and international players. Companies like Syngene International, GVK BIO (now Aragen Life Sciences), and various mid-sized CROs (Contract Research Organizations) are key competitors. Performance metrics like revenue growth and profit margins are crucial for comparison.

Context metrics (time-bound)

• FY26 Standalone Revenue: ₹53.93 crore (vs. ₹43.61 crore in FY25)
• FY26 Standalone Net Profit: ₹1.65 crore (vs. ₹0.74 crore in FY25)
• FY26 Consolidated Revenue: ₹61.54 crore (vs. ₹46.84 crore in FY25)
• FY26 Consolidated Net Profit: ₹1.03 crore (vs. ₹0.06 crore in FY25)

What to track next

Investors should monitor quarterly results for continued revenue and profit growth. Key factors to watch include the company's ability to secure new contracts, expand its service offerings, and manage operational costs effectively. Updates on the clinical research services segment's performance will be crucial.